Reference 2018-87

REF:       2018-87    

Subject:   Asthma patients    

          

 

Request:

  1. In your trust, in the past 3 months [latest 3 months available], how many asthma patients aged 18 and over have been treated?

 

  1. How many paediatric asthma treated patients [aged 6-17] have been treated?

 

  1. How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated?

 

  1. How many severe allergic asthma patients [severe persistent confirmed allergic IgE-mediated asthma OR severe persistent confirmed allergic eosinophilic asthma] have been treated with:

–          Omalizumab [Xolair]

–          Mepolizumab [Nucala]

–          Reslizumab [Cinqaero]

–          Benralizumab [Fasenra]

–          Other [Please state]

 

  1. How many paediatric severe asthma patients treated with Xolair/omalizumab?

 

  1. How many asthma clinics are run per month?

 

  1. What is the average number of severe asthma patients per clinic?

 

  1. Do you treat non asthma patients with Omalizumab [Xolair]?

If yes, how many of for what condition?

 

 

Response:

Please find information attached.

2018-87 – FOI Request – Asthma patients [109 kb] PDF

 

Visitor restrictions

To protect you and our staff during the current outbreak of Covid-19 we’ve put in place significant restrictions on hospital visitors.

Full details of these can be found on our website.

We would like to thank you for your understanding and helping us stop the spread of Covid-19.

Read More

Stay Home. Protect the NHS. Save Lives.

Close